China Biopharma, Inc., a biopharmaceutical company focused on developing and distributing human vaccine products in China, announced that through its subsidiary, Hainan CITIC Biopharmaceutical Development Co., Ltd., it has completed the delivery of 1.5 million doses of flu vaccine in China.

Chairman and CEO of China Biopharma, Inc., Peter Wang, stated, "We are very pleased that our flu vaccine was among the first to be made available to the general public in China for the 2006-2007 Flu Season. The (Chinese) Centres for Disease Control (CDCs) have set a rigorous blueprint to increase the accessibility and affordability to influenza vaccine programs nationwide. Our vision is to become one of China's leading providers of pandemic and seasonal influenza vaccines. Now that we have successfully delivered our first batch of flu vaccines to local CDCs, insurance companies, hospitals, and other facilities, we believe we are on track to deliver a total of three million doses of vaccine by year-end 2006."

China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, Zhejiang Tianyuan Biotech Co., Ltd. and Hainan CITIC Biopharmaceutical Development Co., Ltd., the company develops and distributes human vaccine products throughout the world's most populated country, China. Products include human vaccines against influenza, hemorrhagic fever, and Japanese Encephalitis.